@kadrinpvi.bsky.social
Reposted
I missed this poll but this is a bit scary!!! 8 % said Ribociclib which is absolutely contraindicated and honestly I would be hesitant to start her on any cdk4/6 inhibitor with a QTc that high particularly given she is on seroquel. Speed dial to cardio-oncology! Education needed!
January 31, 2025 at 1:31 AM
I missed this poll but this is a bit scary!!! 8 % said Ribociclib which is absolutely contraindicated and honestly I would be hesitant to start her on any cdk4/6 inhibitor with a QTc that high particularly given she is on seroquel. Speed dial to cardio-oncology! Education needed!
Reposted
Yes!! I hope that when those “interaction checks” come up at prescribing or in the pharmacy check this would get 🚩🚩🚩 red flagged, but this is why we share these scenarios! #oncsky @peerview.bsky.social
I missed this poll but this is a bit scary!!! 8 % said Ribociclib which is absolutely contraindicated and honestly I would be hesitant to start her on any cdk4/6 inhibitor with a QTc that high particularly given she is on seroquel. Speed dial to cardio-oncology! Education needed!
February 1, 2025 at 12:56 AM
Yes!! I hope that when those “interaction checks” come up at prescribing or in the pharmacy check this would get 🚩🚩🚩 red flagged, but this is why we share these scenarios! #oncsky @peerview.bsky.social
Reposted
⭐Thank you everyone for participating in the 2nd poll on diarrhea 💩 management for our patient with HR+, HER2- MBC on a 1L CDK4/6i! Here are the results from that other site for reference 🐦❌ 📊👇
February 1, 2025 at 12:46 AM
⭐Thank you everyone for participating in the 2nd poll on diarrhea 💩 management for our patient with HR+, HER2- MBC on a 1L CDK4/6i! Here are the results from that other site for reference 🐦❌ 📊👇
Reposted
Let’s 🔎 closer at considerations for management of diarrhea 💩 associated with a CDK4/6i Tx. Please watch a short 📹 explaining what I would do. What are your experiences, Qs? Then access the full @PeerView #CME activity and get credit at PeerView.com/AGR @peerview.bsky.social
February 1, 2025 at 12:52 AM
Let’s 🔎 closer at considerations for management of diarrhea 💩 associated with a CDK4/6i Tx. Please watch a short 📹 explaining what I would do. What are your experiences, Qs? Then access the full @PeerView #CME activity and get credit at PeerView.com/AGR @peerview.bsky.social
Reposted
👍Thank you to all of you who participated in my 3rd poll on 2L Tx for a patient with HR+, HER2- #MBC progressing on a 1L CDK4/6i.
Here are the results 📊👇from that other site as a reference
Here are the results 📊👇from that other site as a reference
February 2, 2025 at 1:46 AM
👍Thank you to all of you who participated in my 3rd poll on 2L Tx for a patient with HR+, HER2- #MBC progressing on a 1L CDK4/6i.
Here are the results 📊👇from that other site as a reference
Here are the results 📊👇from that other site as a reference
Reposted
☑️Which of the following 2L Tx options would you recommend for this patient with HR+, HER2- #MBC progressing on 1L palbociclib? Please answer & explain in a comment 💬 why you made the choice you did.
1️⃣Capecitabine
2️⃣Abemaciclib + fulvestrant
3️⃣Exemestane + everolimus
4️⃣Something else (Tell me 💬⬇️)
1️⃣Capecitabine
2️⃣Abemaciclib + fulvestrant
3️⃣Exemestane + everolimus
4️⃣Something else (Tell me 💬⬇️)
February 1, 2025 at 12:54 AM
☑️Which of the following 2L Tx options would you recommend for this patient with HR+, HER2- #MBC progressing on 1L palbociclib? Please answer & explain in a comment 💬 why you made the choice you did.
1️⃣Capecitabine
2️⃣Abemaciclib + fulvestrant
3️⃣Exemestane + everolimus
4️⃣Something else (Tell me 💬⬇️)
1️⃣Capecitabine
2️⃣Abemaciclib + fulvestrant
3️⃣Exemestane + everolimus
4️⃣Something else (Tell me 💬⬇️)
Reposted
Our next case scenario looks at a patient with HR+, HER2- #MBC who has progressed on 1L CDK4/6i 💊 with palbociclib + ET. Please consider the case details, answer the following poll 📊 on what Tx option you would choose next, and share your reason in the comments 💬! @peerview.bsky.social
February 1, 2025 at 12:53 AM
Our next case scenario looks at a patient with HR+, HER2- #MBC who has progressed on 1L CDK4/6i 💊 with palbociclib + ET. Please consider the case details, answer the following poll 📊 on what Tx option you would choose next, and share your reason in the comments 💬! @peerview.bsky.social
Reposted
Thank you for participating in this #OncSky Thread 🧵 on individualizing Tx of HR+, HER2- #MBC. Here are some takeaways. I hope you enjoyed this as much as I did! To participate in the full Peer View #CME activity and to get credit, please visit PeerView.com/AGR.
February 2, 2025 at 1:46 AM
Thank you for participating in this #OncSky Thread 🧵 on individualizing Tx of HR+, HER2- #MBC. Here are some takeaways. I hope you enjoyed this as much as I did! To participate in the full Peer View #CME activity and to get credit, please visit PeerView.com/AGR.
Reposted
Now, let’s explore 2L options in HR+, HER2- #MBC after progression on 1L CDK4/6i. Please watch the short 📹 explaining my choice and rationale. What are your thoughts, Qs? 🙋 Go to 👉 PeerView.com/AGR for full @peerview.bsky.social content & credit.
February 2, 2025 at 1:46 AM
Now, let’s explore 2L options in HR+, HER2- #MBC after progression on 1L CDK4/6i. Please watch the short 📹 explaining my choice and rationale. What are your thoughts, Qs? 🙋 Go to 👉 PeerView.com/AGR for full @peerview.bsky.social content & credit.
Reposted
In addition to starting antidiarrheal tx & ⬆️ hydration to manage persistent/recurrent grade 2 diarrhea 💩 experienced by this patient, you hold ⚠️ abemaciclib until toxicity resolves to grade ≤1. When resuming CDK4/6i 💊 what dose would you use for abema?
1️⃣150 mg BID
2️⃣100 mg BID
3️⃣50 mg BID
4️⃣No idea!
1️⃣150 mg BID
2️⃣100 mg BID
3️⃣50 mg BID
4️⃣No idea!
January 30, 2025 at 12:06 AM
In addition to starting antidiarrheal tx & ⬆️ hydration to manage persistent/recurrent grade 2 diarrhea 💩 experienced by this patient, you hold ⚠️ abemaciclib until toxicity resolves to grade ≤1. When resuming CDK4/6i 💊 what dose would you use for abema?
1️⃣150 mg BID
2️⃣100 mg BID
3️⃣50 mg BID
4️⃣No idea!
1️⃣150 mg BID
2️⃣100 mg BID
3️⃣50 mg BID
4️⃣No idea!
Reposted
Now, let’s 💬⁉️ about individualized selection of CDK4/6i 💊for 1L Tx of HR+, HER2- #MBC. Watch this short 📹 to hear my thoughts on this case, then share your comments + questions. You can also access the full @PeerView activity & claim #CME credits at PeerView.com/AGR @peerview.bsky.social
January 29, 2025 at 11:42 PM
Now, let’s 💬⁉️ about individualized selection of CDK4/6i 💊for 1L Tx of HR+, HER2- #MBC. Watch this short 📹 to hear my thoughts on this case, then share your comments + questions. You can also access the full @PeerView activity & claim #CME credits at PeerView.com/AGR @peerview.bsky.social
Reposted
👏Thank you everyone for participating in our poll #1 on 1L CDK4/6i selection for a patient with ER+, PgR-, HER2- #MBC! Here are the results from that other place for reference 📊👇
@peerview.bsky.social
@peerview.bsky.social
January 29, 2025 at 11:37 PM
👏Thank you everyone for participating in our poll #1 on 1L CDK4/6i selection for a patient with ER+, PgR-, HER2- #MBC! Here are the results from that other place for reference 📊👇
@peerview.bsky.social
@peerview.bsky.social
Reposted
I am eagerly waiting for more answers here, dear #medsky #oncsky. There’s no 📊 poll feature on BlueSky🦋, so we just have to respond!
If we get that total 🗳️ count up, maybe I will reveal how I’m spending my evening tonight before we pick up tomorrow!
#mystery 🤔🕵🏼♀️ #WorkLifeBalance ⚖️
If we get that total 🗳️ count up, maybe I will reveal how I’m spending my evening tonight before we pick up tomorrow!
#mystery 🤔🕵🏼♀️ #WorkLifeBalance ⚖️
🧵Welcome to a fun & informative 3-part #BlueThread on how to make 🎯decisions in HR+, HER2- #MBC, based on a case-based #CME activity I developed with @peerview.bsky.social 👉 PeerView.com/AGR. I’ll post 3 case scenarios with a poll ? 📊, you vote 📲, and we’ll discuss each case. Ready?
January 29, 2025 at 12:32 AM
I am eagerly waiting for more answers here, dear #medsky #oncsky. There’s no 📊 poll feature on BlueSky🦋, so we just have to respond!
If we get that total 🗳️ count up, maybe I will reveal how I’m spending my evening tonight before we pick up tomorrow!
#mystery 🤔🕵🏼♀️ #WorkLifeBalance ⚖️
If we get that total 🗳️ count up, maybe I will reveal how I’m spending my evening tonight before we pick up tomorrow!
#mystery 🤔🕵🏼♀️ #WorkLifeBalance ⚖️
Reposted
T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com
January 28, 2025 at 12:50 AM
Reposted
I hope as you log on this week you’ll check in with me & this thread—will be updating all week with @peerview.bsky.social #bcsm #oncsky
🧵Welcome to a fun & informative 3-part #BlueThread on how to make 🎯decisions in HR+, HER2- #MBC, based on a case-based #CME activity I developed with @peerview.bsky.social 👉 PeerView.com/AGR. I’ll post 3 case scenarios with a poll ? 📊, you vote 📲, and we’ll discuss each case. Ready?
January 28, 2025 at 12:34 AM
I hope as you log on this week you’ll check in with me & this thread—will be updating all week with @peerview.bsky.social #bcsm #oncsky
Reposted
⏰ Time for our case 1️⃣ of a patient with ER+, PgR-, HER2- #MBC who also has well-controlled #mentalhealth and a baseline ❤️ QTc of 575 ms. Review the case details, answer the poll 📊 about your preferred 1L CDK4/6i, & comment 💬 with the rationale. What would you recommend and why?
January 27, 2025 at 11:09 PM
⏰ Time for our case 1️⃣ of a patient with ER+, PgR-, HER2- #MBC who also has well-controlled #mentalhealth and a baseline ❤️ QTc of 575 ms. Review the case details, answer the poll 📊 about your preferred 1L CDK4/6i, & comment 💬 with the rationale. What would you recommend and why?
Reposted
🧵Welcome to a fun & informative 3-part #BlueThread on how to make 🎯decisions in HR+, HER2- #MBC, based on a case-based #CME activity I developed with @peerview.bsky.social 👉 PeerView.com/AGR. I’ll post 3 case scenarios with a poll ? 📊, you vote 📲, and we’ll discuss each case. Ready?
January 27, 2025 at 11:09 PM
🧵Welcome to a fun & informative 3-part #BlueThread on how to make 🎯decisions in HR+, HER2- #MBC, based on a case-based #CME activity I developed with @peerview.bsky.social 👉 PeerView.com/AGR. I’ll post 3 case scenarios with a poll ? 📊, you vote 📲, and we’ll discuss each case. Ready?
Reposted
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
December 24, 2024 at 3:07 AM
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
Reposted
🌟 Faculty Spotlight: Meet Dr. Gordon A. Brown, presenting alongside Dr. Shore at this year’s PeerView symposium, Navigating Therapeutic Choices in Prostate Cancer, during #SUO2024. Join us on 12/6 to explore the latest advancements in #prostatecancer treatment.
📍 Register here: bit.ly/24ProstateT
📍 Register here: bit.ly/24ProstateT
December 4, 2024 at 5:37 PM
🌟 Faculty Spotlight: Meet Dr. Gordon A. Brown, presenting alongside Dr. Shore at this year’s PeerView symposium, Navigating Therapeutic Choices in Prostate Cancer, during #SUO2024. Join us on 12/6 to explore the latest advancements in #prostatecancer treatment.
📍 Register here: bit.ly/24ProstateT
📍 Register here: bit.ly/24ProstateT
Reposted
🔔 2 days left! Are you ready to learn from world-class expert faculty on optimizing #prostatecancer care? 🩺 Explore real-world cases and innovative treatments at #SUO2024 on Friday, Dec 6.
📍 Join us in person or virtually.
🎟️ Sign up now: bit.ly/24ProstateT
#Oncsky #Medsky
📍 Join us in person or virtually.
🎟️ Sign up now: bit.ly/24ProstateT
#Oncsky #Medsky
MDADI
MDADI
bit.ly
December 4, 2024 at 3:28 PM
🔔 2 days left! Are you ready to learn from world-class expert faculty on optimizing #prostatecancer care? 🩺 Explore real-world cases and innovative treatments at #SUO2024 on Friday, Dec 6.
📍 Join us in person or virtually.
🎟️ Sign up now: bit.ly/24ProstateT
#Oncsky #Medsky
📍 Join us in person or virtually.
🎟️ Sign up now: bit.ly/24ProstateT
#Oncsky #Medsky
Reposted
🌟 Faculty Spotlight: Meet Dr. Neal D. Shore, Medical Director of the Carolina Urologic Research Center, leading this year’s #SUO2024 symposium on prostate cancer care.
🗓️ Join Dr. Shore on Dec 6!
📍 In-person or Virtual
👉 Register today: bit.ly/24ProstateT
#Medsky #Prostatecancer #Oncsky
🗓️ Join Dr. Shore on Dec 6!
📍 In-person or Virtual
👉 Register today: bit.ly/24ProstateT
#Medsky #Prostatecancer #Oncsky
December 3, 2024 at 10:15 PM
🌟 Faculty Spotlight: Meet Dr. Neal D. Shore, Medical Director of the Carolina Urologic Research Center, leading this year’s #SUO2024 symposium on prostate cancer care.
🗓️ Join Dr. Shore on Dec 6!
📍 In-person or Virtual
👉 Register today: bit.ly/24ProstateT
#Medsky #Prostatecancer #Oncsky
🗓️ Join Dr. Shore on Dec 6!
📍 In-person or Virtual
👉 Register today: bit.ly/24ProstateT
#Medsky #Prostatecancer #Oncsky
Reposted
⏳ Just 3 days until #ASH2024 kicks off in San Diego! Start your weekend with PeerView's Friday symposia on #CLL, #MDS, and #MF. 🎓 Cutting-edge insights, expert faculty, and actionable takeaways await. See you there!
🔗 bit.ly/Hematology2024T
#Oncsky #HemOnc #Medsky
🔗 bit.ly/Hematology2024T
#Oncsky #HemOnc #Medsky
MDADI
MDADI
bit.ly
December 3, 2024 at 3:14 PM
Reposted
Update to the ASCO guidelines on #SCLC now in JCO. Includes recommending durvalumab after chemoradiation for LS-SCLC based on ADRIATIC and adds recommendation of tarlatamab for relapsed SCLC, joining lurbinectedin and topotecan as options. #LCSM #OncSky
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations
as a response to the emergence of new and practice-changing data. The rapid updates
are supported by an e...
ascopubs.org
November 21, 2024 at 10:49 AM
Update to the ASCO guidelines on #SCLC now in JCO. Includes recommending durvalumab after chemoradiation for LS-SCLC based on ADRIATIC and adds recommendation of tarlatamab for relapsed SCLC, joining lurbinectedin and topotecan as options. #LCSM #OncSky
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Reposted
Join lung cancer experts Drs. @stephenvliu.bsky.social & Zosia Piotrowska on 11/22 at 9:30 AM PST during #MaTOS2024 for an #EGFR-mutated advanced #NSCLC event. Explore updated treatment strategies, new approvals, & evolving guidelines. Register: PeerView.com/LakeTahoe24 🩺
November 19, 2024 at 9:16 PM
Join lung cancer experts Drs. @stephenvliu.bsky.social & Zosia Piotrowska on 11/22 at 9:30 AM PST during #MaTOS2024 for an #EGFR-mutated advanced #NSCLC event. Explore updated treatment strategies, new approvals, & evolving guidelines. Register: PeerView.com/LakeTahoe24 🩺
Reposted
Remember to join us on Thursday, Nov 21, at 5:15 PM CST for our #glioma in-person & virtual symposium during #SNO2024 led by Dr. Manmeet S. Ahluwalia. Please submit your questions in advance and follow @peerview.bsky.social for more #MedEd content! Register here: PeerView.com/2024Glioma
November 19, 2024 at 8:52 PM
Remember to join us on Thursday, Nov 21, at 5:15 PM CST for our #glioma in-person & virtual symposium during #SNO2024 led by Dr. Manmeet S. Ahluwalia. Please submit your questions in advance and follow @peerview.bsky.social for more #MedEd content! Register here: PeerView.com/2024Glioma